Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.47 |
| ▸ | BRD4 | O60885 | 9/20 | 0.47 |
| ▸ | PLK2 | Q9NYY3 | 10/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1288688 | 1.00 | PLK1 (0.47) | PLK1BRD4PLK2PLK3ALDH1A1 | |
| SCHEMBL1288868 | 0.98 | PLK1 (0.49) | PLK1BRD4PLK2PLK3ALDH1A1 | |
| SCHEMBL1288866 | 0.98 | PLK1 (0.49) | PLK1BRD4PLK2PLK3ALDH1A1 | |
| SCHEMBL1288523 | 0.90 | PLK1 (0.49) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288522 | 0.90 | PLK1 (0.49) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288519 | 0.88 | PLK1 (0.47) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288516 | 0.88 | PLK1 (0.47) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288746 | 0.88 | PLK1 (0.48) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288741 | 0.88 | PLK1 (0.48) | PLK1BRD4PLK2PLK3 | |
| SCHEMBL1288520 | 0.87 | PLK1 (0.42) | PLK1BRD4PLK2PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661268-A2 | INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | PLK1 1/4885BRD4 1149/4885PLK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.